Page last updated: 2024-11-06

benzyloxycarbonylarginine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Benzyloxycarbonylarginine (Z-Arg) is a synthetic amino acid derivative commonly used in peptide synthesis. It is an N-protected arginine, where the amino group is protected by a benzyloxycarbonyl (Z) group. This protection strategy allows for selective reactions to occur at other functional groups within the peptide chain. Z-Arg is typically synthesized by reacting arginine with benzyl chloroformate in an alkaline solution. The compound is widely used in solid-phase peptide synthesis (SPPS) as a building block for creating peptides containing arginine residues. Its importance lies in its ability to provide a temporary protection of the amino group, preventing unwanted side reactions and ensuring efficient peptide assembly. Z-Arg is also studied for its potential applications in medicinal chemistry, where it can be used to develop drugs with enhanced stability and bioavailability. The protected arginine residue can be readily removed after peptide synthesis using strong acids or hydrogenolysis, leading to the desired peptide product.'

Cross-References

ID SourceID
PubMed CID71055
CHEMBL ID1423296
SCHEMBL ID631840
MeSH IDM0070025

Synonyms (58)

Synonym
AC-17163
1234-35-1
l-arginine, n2-[(phenylmethoxy)carbonyl]-
MLS000563719 ,
smr000388882
SDCCGMLS-0091585.P001
benzyloxycarbonylarginine
UPCMLD00WJLM29
CMLD4_000213
z-arg-oh, >=96.0% (nt)
z-arg-oh
nalpha-cbz-l-arginine
nalpha-carbobenzoxy-l-arginine
(2s)-5-(diaminomethylideneamino)-2-(phenylmethoxycarbonylamino)pentanoic acid
A805075
(s)-2-(((benzyloxy)carbonyl)amino)-5-((diaminomethylene)ammonio)pentanoate
NCGC00247325-01
M03028
cbz-arg-oh
HMS2214B21
z-l-arg-oh
benzyloxycarbonyl-l-arginine
einecs 214-973-6
n2-((phenylmethoxy)carbonyl)-l-arginine
l-arginine, n2-((phenylmethoxy)carbonyl)-
(2s)-5-[bis(azanyl)methylideneamino]-2-(phenylmethoxycarbonylamino)pentanoic acid
(2s)-2-(benzyloxycarbonylamino)-5-guanidino-valeric acid
bdbm94463
cid_71055
AKOS015895268
(2s)-2-{[(benzyloxy)carbonyl]amino}-5-carbamimidamidopentanoic acid
n~2~-[(benzyloxy)carbonyl]-l-arginine
STL466178
SCHEMBL631840
(s)-n2-(benzyloxycarbonyl)-arginine
J-300035
cbz-l-arginine
CHEMBL1423296
arginine, n2-[(phenylmethoxy)carbonyl]-
n-.alpha.-cbz-l-arginine
n-carbobenzoxy-l-arginine
arginine, n2-carboxy-, n2-benzyl ester, l-
n2-benzyloxycarbonyl-l-arginine
n-2-carbobenzyloxy-l-arginine
arginine, n-(benzyloxy)carbonyl-
n-.alpha.-(benzyloxycarbonyl)arginine, l-
n-alpha-benzyloxycarbonyl-l-arginine (cbz-arg-oh)
n-alpha-benzyloxycarbonyl-l-arginine
(2s)-5-(diaminomethylideneammonio)-2-(phenylmethoxycarbonylamino)pentanoate
R40 ,
(s)-2-(benzyloxycarbonylamino)-5-guanidinopentanoic acid
AS-12757
((benzyloxy)carbonyl)-l-arginine
D78041
DTXSID20883670
EN300-302867
CS-W012075
HY-W011359
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
lamin isoform A-delta10Homo sapiens (human)Potency5.01190.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]